WILATE

This brand name is authorized in United States. It is also authorized in Austria, Brazil, Canada, Croatia, Ecuador, Estonia, Finland, Ireland, Israel, Lithuania, Malta, Netherlands, New Zealand, Poland, Romania, Spain, Tunisia, UK.

Active ingredients

The drug WILATE contains a combination of these active pharmaceutical ingredients (APIs):

1	Human factor VIII UNII 839MOZ74GK - ANTIHEMOPHILIC FACTOR HUMAN
	Activated factor VIII acts as a cofactor for activated factor IX, accelerating the conversion of factor X to activated factor X (factor Xa). Haemophilia A is a sex-linked hereditary disorder of blood coagulation due to decreased levels of factor VIII:C. By replacement therapy the plasma levels of factor VIII are increased, thereby enabling a temporary correction of the factor deficiency and correction of the bleeding tendencies.
	Read more about Coagulation factor VIII
2	Von Willebrand factor UNII ZE22NE22F1 - VON WILLEBRAND FACTOR HUMAN
	Administration of von Willebrand factor allows correction of the haemostatic abnormalities exhibited by patients who suffer from von Willebrand factor deficiency.
	Read more about Von Willebrand factor

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
WILATE Powder and solvent for solution for injection	MPI, EU: SmPC	Health Products Regulatory Authority (IE)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
B02BD06	Von Willebrand factor and coagulation factor VIII in combination	B Blood and blood forming organs → B02 Antihemorrhagics → B02B Vitamin K and other hemostatics → B02BD Blood coagulation factors
Discover more medicines within B02BD06

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	535315040002107, 535315040002207, 535317070002707, 535317070002807
CA	Health Products and Food Branch	02286750, 02286769
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	105-MBE-0617, 99-MBE-0517
EE	Ravimiamet	1503593, 1503605
ES	Centro de información online de medicamentos de la AEMPS	75625, 75648
FI	Lääkealan turvallisuus- ja kehittämiskeskus	407358, 417307
GB	Medicines & Healthcare Products Regulatory Agency	263058, 263068
HR	Agencija za lijekove i medicinske proizvode	HR-H-138328484, HR-H-758724968
IL	מִשְׂרַד הַבְּרִיאוּת	7716, 7717
LT	Valstybinė vaistų kontrolės tarnyba	1057510, 1057511, 1091499
MT	Medicines Authority	MA1219/01101, MA1219/01102
NL	Z-Index G-Standaard, PRK	100404, 100412
NZ	Medicines and Medical Devices Safety Authority	12483, 12484
PL	Rejestru Produktów Leczniczych	100270469, 100270475
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W65361001, W65362001
TN	Direction de la Pharmacie et du Médicament	10043041H, 10043042H
US	FDA, National Drug Code	68982-182